

**From:** [REDACTED]  
**Sent:** 29 September 2010 18:48  
**Cc:** ORTUN SILVAN Pedro (ENTR); [REDACTED] (ENTR); ENTR /F/5 FOOD HEALTH BIOTECH  
**Subject:** Next steps: 1st Steering Group meeting on access to medicines in Europe

*To: Members of the Steering Group,*

*Copy: To whom it may concern*

**Dear Member of the Steering Group meeting on access to medicines in Europe,**

On behalf of the chair Mr Ortún, we would like to thank you for the fruitful meeting on Friday 24 September, and as we agreed, to summarise in a brief email the next steps we agreed on. You will find attached the slides that were presented. The minutes of the meeting will be drafted and should be sent to you for comments in due time.



Presentation -  
meeting with SG...

**1. On the Platform on access to medicines in Europe**

a. Terms of reference

**Members are invited to send comments and concrete suggestions on the document by 15 October.** A revised version of the document will be drafted and submitted for adoption at the next Steering Group meeting.



201000920 Draft  
Terms of Refer...

b. Working methods

Members requested the development of working methods for the Steering Group. **Members are invited to send concrete suggestions for working methods by 15 October.** A document will be drafted based on the contributions and submitted for adoption at the next Steering Group meeting.

c. Next meeting

Members requested a next meeting to take place by the end of the year to agree on the terms of reference, working methods and any other aspects related to the projects. The **next meeting of the steering group might take place end of the week of 13 December.** The exact date will be sent in due time.

**2. On the Projects of the platform on access to medicines in Europe**

a. List of the projects

The projects proposed for the platform in the terms of reference were welcomed by the members.

It was nevertheless suggested to add another project on *the identification of areas with the highest medical needs for a prioritisation of medicines development, in the context of pricing and*

*reimbursement decisions.* The report *Priority Medicines for Europe and the World*, commissioned by the Dutch Government during their Presidency in 2004, was referred to as a good starting point. ([http://whqlibdoc.who.int/hq/2004/WHO\\_EDM\\_PAR\\_2004.7.pdf](http://whqlibdoc.who.int/hq/2004/WHO_EDM_PAR_2004.7.pdf) )

**Members, and in particular representatives of the Netherlands and Norway, are invited to send concrete suggestions for a proposal to be drafted and submitted to the next steering group meeting.**

b. Call for interest and launch of the projects

**Members are requested to communicate their INTEREST and send names of EXPERTS to participate in one or more projects. One expert by organisation and by project will be accepted for the time-being. Names and contact details of experts should be sent by 15 October.** After that date, participants in each of the projects will be contacted by the Commission services while the steering group will be kept informed on the development of each projects.

1. Mechanism of coordinated access to orphan medicinal
2. Capacity building on contractual agreements for innovative medicines
3. Facilitating the supply in small countries
4. Promoting a good governance for non- prescription drugs
5. Market access for biosimilars

c. Leadership

Projects will be led by the Commission. Nevertheless, Member States could express an interest to support the Commission in its leadership. **INTEREST of Member States should be communicated y 15 October.**

Do not hesitate to contact me should you have any questions or should you need clarification on one of those points. We would also very much appreciate if you could inform us who from your organisation should be copied in any communication to the steering group members.

Please send me directly your interest in the projects, contributions or comments.

Kind regards,

[Redacted signature]

[Redacted name]

European Commission  
Enterprise & Industry Directorate General  
Unit F5: Competitiveness in the Pharmaceutical Industry and Biotechnology  
[http://ec.europa.eu/enterprise/sectors/healthcare/index\\_en.htm](http://ec.europa.eu/enterprise/sectors/healthcare/index_en.htm)  
Tel: +32 [Redacted]  
Fax: +32 2 292 13 65